Tango Therapeutics, Inc. (TNGX) stock analysis
TNGX · Tango Therapeutics, Inc.
Latest recorded price: USD 24.17
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth 35.9%, free cash flow margin -224.3%. The model flags 1 risk signal for this company (1 high severity).
Similar companies in Healthcare
- Taysha Gene Therapies, Inc. - Common Stock (TSHA)
- Travere Therapeutics, Inc. - Common Stock (TVTX)
- UroGen Pharma Ltd. (URGN)
- Vericel Corporation (VCEL)
- Vir Biotechnology, Inc. (VIR)
- Viking Therapeutics, Inc. - Common Stock (VKTX)
- Viridian Therapeutics, Inc. (VRDN)
- Vertex Pharmaceuticals Incorporated - Common Stock (VRTX)